SCHEMBL4486946

SCHEMBL4486946

CCOC(=O)c1c(NC2CCCC2)sc(C(=O)c2cc(-c3ccccc3)no2)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
HPGD P15428 6/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GRM6 O15303 2/20 0.40
ALOX15 P16050 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
XBP1 P17861 1/20 0.40
ALDH1A1 P00352 5/20 0.38
MAPT P10636 3/20 0.38
HSD17B10 Q99714 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CASP3 P42574 1/20 0.38
LMNA P02545 2/20 0.38
PTBP1 P26599 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472754 0.89 KDM4E (0.41) KDM4ESMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3816591 0.88 LMNA (0.40) KDM4ESMN1; SMN2RAB9ANPC1MEN1
SCHEMBL4479273 0.86 KDM4E (0.43) KDM4ESMN1; SMN2RAB9ANPC1MEN1
SCHEMBL4484825 0.86 KDM4E (0.43) KDM4ESMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3824051 0.81 USP30 (0.44) KDM4EHPGDSMN1; SMN2KMT2AALDH1A1
SCHEMBL3818041 0.81 KDM4E (0.37) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL4467624 0.80 USP30 (0.43) KDM4EHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL13711688 0.78 KDM4E (0.39) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL4466084 0.78 USP30 (0.41) SMN1; SMN2RAB9AMAPTLMNATP53
SCHEMBL4476832 0.78 USP30 (0.46) KDM4EHPGDSMN1; SMN2RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A KDM4E 1483/4885HPGD 319/4885SMN1; SMN2 1379/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A KDM4E 1483/4885HPGD 319/4885SMN1; SMN2 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.